HomeClinical TopicsFDA permits marketing of device to help reduce opioid withdrawal symptoms

FDA permits marketing of device to help reduce opioid withdrawal symptoms

Author(s):

On Nov. 15, the U.S. Food and Drug Administration (FDA) granted a new indication to an electric stimulation device (NSS-2 Bridge) for use in helping to reduce the symptoms of opioid withdrawal. Read more via Fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content